All News Incannex Healthcare Inc.

Equities

IXHL

US45333F1093

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
2.5 ^USD	-10.07%		-1.57%	-46.12%

May. 07	Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder	CI
Mar. 05	Incannex Healthcare Inc. Announces CFO Changes	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder	May. 07	AQ
Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder	May. 07	CI
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)	May. 01	NE
Incannex Healthcare Inc. Quarterly Update, Q1 2024	Apr. 16	AQ
Incannex Healthcare Inc. Announces CFO Changes	Mar. 05	CI
Incannex Healthcare Inc. Announces Executive Changes	Mar. 05	CI
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	Feb. 28	CI
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	Feb. 28	AQ
Incannex Healthcare Completes Pre-Investigational New Drug Meeting on CannQuit-N With US FDA	Feb. 16	MT
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation	Feb. 16	AQ
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N	Feb. 16	CI
Incannex Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14	CI
Clarion Clinics Open for Psychedelic-Assisted Treatments	Feb. 01	AQ
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	Jan. 24	AQ
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	Jan. 24	CI
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences	Jan. 18	AQ
Incannex Completes Dosing and Therapy in Phase 2 ?Psigad? Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder	Jan. 18	CI
Incannex Healthcare Gets Institutional Review Board Approval For IHL-42X Drug Trial	Jan. 17	MT
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	Jan. 17	AQ
Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	Jan. 17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Incannex Healthcare Inc.

Equities

IXHL

US45333F1093

All News

Filters